Yellow Fever Drug Development Pipeline Study, H2 2018
Yellow Fever Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Yellow Fever pipeline products.
DISEASE OVERVIEW
Yellow fever is a mosquito-borne infection that ranges from causing mild fever in infected person to aches and pains and can also progress to serious liver damage and jaundice.
A single dose of vaccine is administered to immunize against yellow fever
United Nations (UN) plans to eradicate yellow fever completely in Africa by 2026 through mass vaccination campaigns.
African and South American population is most affected by yellow fever due to low vaccination levels. Around 90% of deaths worldwide are reported in African countries.
Worldwide, an estimated 0.2 million persons are infected with yellow fever annually. Of these, around 30,000 patients die due to progress in yellow fever. UNICEF currently has agreements with 4 drug companies and procures 30+ million vaccines annually for administering children and adults in African markets.
Accordingly, to gain from the huge market potential, 10 companies are currently investing their research and development efforts on developing vaccines and treatment options for yellow fever infection. Companies currently actively involved in the yellow fever infection pipeline include%li%BioCryst Pharmaceuticals Inc, Emergex Vaccines Ltd, Ennaid Therapeutics LLC, GE Healthcare Life Sciences, Heat Biologics, Inc., iBio Inc, KinoPharma Inc, Najit Technologies, Sihuan Pharmaceutical Holdings Group Ltd and Takeda Pharmaceuticals.
REPORT DESCRIPTION
The Yellow Fever pipeline guide presents complete overview of drugs currently being developed for Yellow Fever. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Yellow Fever pipeline candidate.
Research and Development progress along with latest news related to each of the Yellow Fever pipeline candidates is included.
Major companies participating in therapeutic development of Yellow Fever are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Yellow Fever from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Yellow Fever clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Yellow Fever pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF YELLOW FEVER PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Yellow fever is a mosquito-borne infection that ranges from causing mild fever in infected person to aches and pains and can also progress to serious liver damage and jaundice.
A single dose of vaccine is administered to immunize against yellow fever
United Nations (UN) plans to eradicate yellow fever completely in Africa by 2026 through mass vaccination campaigns.
African and South American population is most affected by yellow fever due to low vaccination levels. Around 90% of deaths worldwide are reported in African countries.
Worldwide, an estimated 0.2 million persons are infected with yellow fever annually. Of these, around 30,000 patients die due to progress in yellow fever. UNICEF currently has agreements with 4 drug companies and procures 30+ million vaccines annually for administering children and adults in African markets.
Accordingly, to gain from the huge market potential, 10 companies are currently investing their research and development efforts on developing vaccines and treatment options for yellow fever infection. Companies currently actively involved in the yellow fever infection pipeline include%li%BioCryst Pharmaceuticals Inc, Emergex Vaccines Ltd, Ennaid Therapeutics LLC, GE Healthcare Life Sciences, Heat Biologics, Inc., iBio Inc, KinoPharma Inc, Najit Technologies, Sihuan Pharmaceutical Holdings Group Ltd and Takeda Pharmaceuticals.
REPORT DESCRIPTION
The Yellow Fever pipeline guide presents complete overview of drugs currently being developed for Yellow Fever. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Yellow Fever pipeline candidate.
Research and Development progress along with latest news related to each of the Yellow Fever pipeline candidates is included.
Major companies participating in therapeutic development of Yellow Fever are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Yellow Fever from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Yellow Fever clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Yellow Fever pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF YELLOW FEVER PIPELINE REPORT INCLUDES
- Panorama of Yellow Fever pipeline markets including statistics on therapeutic drugs and companies involved
- Yellow Fever Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Yellow Fever pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Yellow Fever pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Yellow Fever pipeline therapeutics
- Get clear understanding of the entire Yellow Fever pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Yellow Fever pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Yellow Fever Pipeline include-
Number of Companies with Yellow Fever projects in pre-clinical Development-
Number of Companies with Yellow Fever projects in Clinical Development-
Yellow Fever Pipeline Companies based in Americas
Yellow Fever Pipeline Companies based in Europe
Yellow Fever Pipeline Companies based in Asia Pacific
Yellow Fever Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Yellow Fever Pipeline Agents in pre- clinical/Discovery stage of Development
Yellow Fever Pipeline Agents in Clinical Development stage
Yellow Fever Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Yellow Fever Pipeline agents
II. INSIGHTS INTO YELLOW FEVER PIPELINE
1. Disease Overview
Introduction to Yellow Fever
Symptoms and Causes of Yellow Fever
Treatment or Prevention Options for Yellow Fever
Other Details
2. Phase wise Pipeline Compounds
Yellow Fever Pipeline- Pre- Clinical/Discovery stage Drugs
Yellow Fever Pipeline- Phase 1 stage Drugs
Yellow Fever Pipeline- Phase 2 stage Drugs
Yellow Fever Pipeline- Phase 3 stage Drugs
Yellow Fever Pipeline- Pre-Registration stage Drugs
3. Company wise Yellow Fever Pipeline Compounds
4. Yellow Fever Pipeline by Mechanism of Action
III. YELLOW FEVER PIPELINE COMPOUND DETAILS
Galidesivir
EMX-001
anti-viral peptide for Yellow Fever
XRX
gp96-based vaccines
yellow fever vaccine
RNA virus Infections
Yellow fever vaccine
JK-05
Yellow Fever (YF-17D) Vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. YELLOW FEVER PIPELINE COMPANY BRIEFS
BioCryst Pharmaceuticals Inc
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
GE Healthcare Life Sciences
Heat Biologics, Inc.
iBio Inc
KinoPharma Inc
Najit Technologies Inc
Sihuan Pharmaceutical Holdings Group Ltd
Takeda Pharmaceutical Company Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL YELLOW FEVER PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Yellow Fever Pipeline include-
Number of Companies with Yellow Fever projects in pre-clinical Development-
Number of Companies with Yellow Fever projects in Clinical Development-
Yellow Fever Pipeline Companies based in Americas
Yellow Fever Pipeline Companies based in Europe
Yellow Fever Pipeline Companies based in Asia Pacific
Yellow Fever Pipeline Companies based in Rest of the World
2. Pipeline Candidates include-
Yellow Fever Pipeline Agents in pre- clinical/Discovery stage of Development
Yellow Fever Pipeline Agents in Clinical Development stage
Yellow Fever Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Yellow Fever Pipeline agents
II. INSIGHTS INTO YELLOW FEVER PIPELINE
1. Disease Overview
Introduction to Yellow Fever
Symptoms and Causes of Yellow Fever
Treatment or Prevention Options for Yellow Fever
Other Details
2. Phase wise Pipeline Compounds
Yellow Fever Pipeline- Pre- Clinical/Discovery stage Drugs
Yellow Fever Pipeline- Phase 1 stage Drugs
Yellow Fever Pipeline- Phase 2 stage Drugs
Yellow Fever Pipeline- Phase 3 stage Drugs
Yellow Fever Pipeline- Pre-Registration stage Drugs
3. Company wise Yellow Fever Pipeline Compounds
4. Yellow Fever Pipeline by Mechanism of Action
III. YELLOW FEVER PIPELINE COMPOUND DETAILS
Galidesivir
EMX-001
anti-viral peptide for Yellow Fever
XRX
gp96-based vaccines
yellow fever vaccine
RNA virus Infections
Yellow fever vaccine
JK-05
Yellow Fever (YF-17D) Vaccine
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. YELLOW FEVER PIPELINE COMPANY BRIEFS
BioCryst Pharmaceuticals Inc
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
GE Healthcare Life Sciences
Heat Biologics, Inc.
iBio Inc
KinoPharma Inc
Najit Technologies Inc
Sihuan Pharmaceutical Holdings Group Ltd
Takeda Pharmaceutical Company Ltd
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL YELLOW FEVER PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
